Skip to main content
Fig. 2 | Journal of Hematology & Oncology

Fig. 2

From: Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial

Fig. 2

Overall survival probability by response. a Kaplan–Meier estimate of overall survival for patients with CR/CRh (n = 21), other responders (n = 13), and non-responders (n = 33). Other responders are patients with CRi, MLFS, or PR. Non-responders are patients in response assessment categories other than CR, CRh, CRi, PR, and MLFS. b Kaplan–Meier estimate of overall survival in patients who had prior olutasidenib (OLU) therapy or no prior olutasidenib therapy. c Kaplan–Meier estimate of overall survival in patients who had prior hypomethylating agent (HMA) or no prior HMA. CR, complete remission; CRh, CR with partial hematologic recovery; CRi, CR with incomplete recover; MLFS, morphologic leukemia-free state; PR, partial remission

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us